StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$3.23+0.36 (+12.54%)

Close on Nov 16, 2026Market cap $265.01MP/E –Yield –

Lexeo Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Lexeo Therapeutics's operating margin for the twelve months ending Dec 31, 2022 was -9252.1%. For fiscal 2022 it was -9252.1%.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2022Dec 31, 2022-9252.1%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2022Sep 30, 2022-3292.3%–

More Lexeo Therapeutics figures

See a number that looks wrong?